SpyGlass Pharma Reports Q3 Results for Quarter Ended June 30, 2026

What Happened
SpyGlass Pharma, Inc. announced its financial results for the quarter ended June 30, 2026 in a press release dated August 6, 2026. The press release was furnished with the company’s Current Report on Form 8-K (Item 2.02) and is included as Exhibit 99.1 to the filing. The report was signed by Chief Financial Officer Jean‑Frédéric Viret, Ph.D., on August 6, 2026.

Key Details

• Filing: Current Report on Form 8-K filed August 6, 2026 (Item 2.02: Results of Operations and Financial Condition).
• Press release: Exhibit 99.1 attached to the 8-K (dated August 6, 2026).
• Interactive data: Exhibit 104 (Cover Page Interactive Data File) included.
• Signature: Report signed by CFO Jean‑Frédéric Viret, Ph.D., on August 6, 2026.

Why It Matters
This 8-K signals SpyGlass has publicly released its quarterly earnings and financial condition update — information investors use to assess recent revenue, expenses, cash position and near-term prospects. The 8-K itself furnishes the press release but does not embed the financial figures in the filing text; investors should read Exhibit 99.1 (the press release) for the specific revenue, earnings, and other metrics. Quarterly results can influence the stock price and investor decisions, so review the full press release and any subsequent filings for detailed numbers and commentary.